Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.76 AUD | 0.00% | +0.57% | -8.57% |
Mar. 19 | Cyclopharm's Technegas Device Carries Out Imaging of First US Patients | MT |
Mar. 18 | Cyclopharm Limited(ASX:CYC) added to S&P/ASX All Ordinaries Index | CI |
Sales 2024 * | 37.4M 24.37M | Sales 2025 * | 60.9M 39.69M | Capitalization | 166M 108M |
---|---|---|---|---|---|
Net income 2024 * | -2M -1.3M | Net income 2025 * | 11M 7.17M | EV / Sales 2024 * | 4.43 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.72 x |
P/E ratio 2024 * |
-70.5
x | P/E ratio 2025 * |
14.4
x | Employees | 87 |
Yield 2024 * |
0.57% | Yield 2025 * |
3.46% | Free-Float | 45.15% |
1 week | +0.57% | ||
Current month | -1.95% | ||
1 month | -1.12% | ||
3 months | -1.40% | ||
6 months | -9.74% | ||
Current year | -8.57% |
Managers | Title | Age | Since |
---|---|---|---|
James McBrayer
CEO | Chief Executive Officer | 58 | 08-06-02 |
Mathew Farag
COO | Chief Operating Officer | - | 16-12-31 |
Mark Doverty
PRN | Corporate Officer/Principal | - | 19-09-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dianne Angus
BRD | Director/Board Member | 63 | 21-08-09 |
James McBrayer
CEO | Chief Executive Officer | 58 | 08-06-02 |
David Heaney
CHM | Chairman | 79 | 06-11-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 1.76 | 0.00% | 13 954 |
24-04-29 | 1.76 | +0.57% | 7,385 |
24-04-26 | 1.75 | 0.00% | 220 |
24-04-24 | 1.75 | -1.69% | 18,513 |
Delayed Quote Australian S.E., April 30, 2024 at 01:59 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.57% | 109M | |
+8.69% | 220B | |
+6.69% | 183B | |
+10.90% | 133B | |
+25.41% | 107B | |
+0.27% | 63.05B | |
+12.72% | 51.74B | |
+3.96% | 50.47B | |
+0.40% | 40.91B | |
+15.03% | 40.59B |
- Stock Market
- Equities
- CYC Stock